Abstract
With the availability of all-oral, direct acting antivirals (DAAs), hepatitis C virus (HCV) therapy has been revolutionized for HIV/HCV co-infected patients. Indeed HCV cure rates are now no longer different between HCV mono and HIV/HCV co-infected persons and are both greater than 95%. Therefore, current treatment guidelines no longer separate these two groups. Indications for HCV treatment and choice of DAA combination are now the same for all HCV patients. In HIV/HCV co-infection however, drug interactions between HIV and HCV agents need be checked prior to starting HCV therapy. Finally, the higher risk of hepatic decompensation in HIV/HCV co-infected patients, including those receiving successful antiretroviral therapy, continues to make these patients a high priority group for receiving access to modern DAA combination therapy.
References
Dec 4, 2003·Lancet·Nazifa QurishiUlrich Spengler
Jul 30, 2004·The New England Journal of Medicine·Francesca J TorrianiUNKNOWN APRICOT Study Group
Sep 27, 2005·Journal of Hepatology·Norbert BräuMaribel Rodríguez-Torres
May 21, 2013·Annals of Internal Medicine·Mark S SulkowskiVincent Soriano
Jun 19, 2013·The Lancet Infectious Diseases·Mark SulkowskiUNKNOWN P05411 study investigators
Jul 23, 2013·HIV Medicine·D GrintUNKNOWN EuroSIDA in EuroCoord
Jan 17, 2014·The New England Journal of Medicine·Mark S SulkowskiUNKNOWN AI444040 Study Group
Jul 20, 2014·JAMA : the Journal of the American Medical Association·Mark S SulkowskiUNKNOWN PHOTON-1 Investigators
Aug 27, 2014·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Juan BerenguerUNKNOWN GESIDA HIVHCV Cohort Study Group
Sep 7, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Douglas DieterichWolfgang Jessner
Dec 9, 2014·Human Vaccines & Immunotherapeutics·Ana MartínezFor The Study Of Hepatitis A In Catalonia
Jan 24, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·David R NelsonUNKNOWN ALLY-3 Study Team
Feb 11, 2015·Lancet·Jean-Michel MolinaUNKNOWN PHOTON-2 study team
Feb 24, 2015·JAMA : the Journal of the American Medical Association·Mark S SulkowskiThomas Podsadecki
Feb 24, 2015·JAMA : the Journal of the American Medical Association·Anu OsinusiShyam Kottilil
Jul 21, 2015·The New England Journal of Medicine·UNKNOWN INSIGHT START Study GroupJames D Neaton
Aug 8, 2015·Gastroenterology·Graham R FosterUNKNOWN BOSON Study Group
Citations
Mar 13, 2018·Clinical Orthopaedics and Related Research·Siddharth A MahureRan Schwarzkopf
Apr 18, 2018·Alimentary Pharmacology & Therapeutics·C-H LiuJ-H Kao
Mar 5, 2019·AIDS Care·Martha ShumwayElise D Riley
Sep 23, 2020·SICOT-J·Christopher FangEric L Smith
Feb 23, 2017·Infectious Diseases of Poverty·Bakyt B KarabaevManas K Akmatov
Jul 25, 2017·JB & JS Open Access·Siddharth A MahureRan Schwarzkopf
Mar 16, 2017·HIV Medicine·M E SocíasM-J Milloy
May 16, 2020·BMC Infectious Diseases·Benard ChimunguChengsong Wan